Exact Sciences Corporation

Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division (doing business as Exact), operates as a pure prime contractor delivering specialized cancer genomic diagnostic testing to federal healthcare agencies, with 100% of recent awards as prime contractor and no subcontractor engagement. The company is headquartered in Madison, Wisconsin, as a subsidiary of Abbott Laboratories, and competes full-and-open across civilian federal healthcare and Department of Defense medical systems with no set-aside designation across its federal footprint.

Exact Sciences' core federal capability centers on proprietary gene expression profiling assays—primarily the Oncotype DX family of mRNA expression tests that analyze cancer tumor tissue to assess recurrence risk and predict treatment responsiveness across breast, prostate, and colorectal cancers. The company also delivers Cologuard colorectal cancer screening tests, Oncoguard liver testing, and broader reference laboratory cancer diagnostic services. Representative work includes a $1.48 million BPA call awarded by VA Strategic Acquisition Center Frederick in August 2025 for VHA breast cancer molecular testing under the GSA Medical Laboratory Testing and Analysis Services (FSS-621-II) schedule; a $932 thousand delivery order from Veterans Integrated Service Network 8 in October 2022 for gene expression testing services extending through February 2026; and a $777 thousand delivery order from Defense Health Agency in August 2025 for Oncotype DX breast cancer assays at Fort Belvoir through February 2030.

Customer concentration is heavily skewed toward the Department of Veterans Affairs across multiple regional networks, which accounts for the majority of awards. The top five funding entities by combined potential value represent 87% of the portfolio: Veterans Integrated Service Network 12 ($39.9 million across 10 awards), Veterans Integrated Service Network 17 ($6.8 million across 18 awards), Defense Health Agency ($6.7 million across 28 awards), VA Strategic Acquisition Center Frederick ($6.3 million across 4 awards), and Veterans Integrated Service Network 15 ($4.1 million across 36 awards). The split between award count and dollar value reveals VISN 12's dominance in dollars despite placing fewer awards than VISN 15 or Defense Health Agency, which place many smaller individual test-order calls. Exact Sciences serves 21 distinct federal customer agencies across the VA health system and Department of Defense medical commands.

Exact Sciences holds six named parent vehicles, all under the GSA Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule: 196 task orders carrying $37.1 million combined potential value across the FSS schedule itself, plus four single-award BPAs and one single-award IDIQ. The largest indefinite vehicles include a $4 million BPA with VISN 17 through August 2028 for Oncotype DX assays, a $1.07 million BPA with VISN 15 through March 2027 spanning seven VA medical facilities in the central United States, a $690 thousand BPA with VISN 6 through March 2029, and a $345 thousand single-award IDIQ with Defense Health Agency through July 2031 for cancer reference laboratory services. These vehicles enable task-order issuance across multiple VA medical centers and military hospitals nationwide.

Activity has remained stable year-over-year, with 19 awards in 2022 rising to 21 awards in both 2024 and 2025, then declining to 12 in the partial 2026 data. Seventeen awards (combined potential value $3.9 million) face ultimate completion within the next twenty-four months, representing recompete exposure concentrated in smaller BPA calls and quarterly express-report orders. SCI-reported invoicing totaled $518 thousand in FY2025 across 0.1 FTEs, reflecting the labor-light nature of reference laboratory testing — work is almost entirely self-performed with zero subcontractor hours across SCI-reportable prime contracts, consistent with Exact Sciences' fully vertical integration of lab operations.

Exact Sciences competes exclusively under full-and-open procurement, holding no SBA set-aside certifications and winning no set-aside-designated awards across the federal footprint. The company's competitive moat rests on proprietary assay technology (particularly Oncotype DX exclusivity) and established presence on the GSA FSS schedule, which enables federal agencies to place sole-source BPA calls directly to Exact Sciences without competition. Multiple BPA descriptions explicitly cite Exact Sciences as the sole source capable of providing the required Oncotype DX assays, particularly for VHA breast cancer molecular testing work. Corporate structure includes four named subsidiaries: Exact Sciences Laboratories, LLC (the performing division for federal contracts); Preventiongenetics LLC; Exact Sciences Thrive LLC; and Genomic Health, Inc., acquired through Exact Sciences' broader corporate strategy in precision oncology diagnostics.